Influenza Vaccines Market Size & Share 2026-2035

Influenza Vaccines Market Size

The global influenza vaccines market was valued at USD 9 billion in 2025. The market is expected to grow from USD 9.5 billion in 2026 to USD 17.4 billion in 2035, growing at a CAGR of 7% during the forecast period, according to the latest report published by Global Market Insights Inc.

The market is primarily stimulated by increasing prevalence of influenza infections, which affect millions of individuals annually across all age groups. As per the WHO, each year, an estimated billion cases of seasonal influenza are recorded, including 3–5 million cases of severe illness. The disease is known to cause 290,000 to 650,000 deaths annually.
 

The influenza vaccines market refers to the global industry focused on preventive immunization against circulating influenza viruses. These vaccines aim to reduce infection risk, prevent severe illness, and improve population‑level protection, particularly for vulnerable groups such as infants, older adults, pregnant women, and individuals with chronic health conditions. Influenza vaccines include a broad range of formulations, such as inactivated vaccines, live attenuated vaccines, recombinant protein vaccines, and cell‑based vaccines, each designed to enhance immune response and adapt to evolving viral strains.
 

Key players stimulating market growth include Sanofi, GlaxoSmithKline, CSL Seqirus, AstraZeneca, and Sinovac Biotech. Some of the key attributes of the leading players include active involvement in vaccine development, large‑scale production, and global distribution. These companies have collaborated with the global and regional government agencies and non-profit organizations such as the WHO and the CDC surveillance systems, contributing to annual strain selection, and investing in advanced manufacturing technologies to improve vaccine effectiveness and availability. Their strategic initiatives, research capabilities, and global distribution network plays a crucial role in expanding influenza vaccine coverage, strengthening preparedness, and ensuring timely access to immunization across diverse regions worldwide.
 

Between 2022 and 2024, the influenza vaccines market experienced notable growth, driven by increased post‑pandemic awareness, stronger vaccination campaigns, and global readiness efforts. The global market was valued at about USD 7.8 billion in 2022 and reached around USD 8.6 billion in 2024. During this period, growth in the market was driven by heightened post-pandemic awareness of respiratory infections and stronger government-led vaccination campaigns. Increased uptake among high-risk groups supported higher vaccination volumes. In addition, increased availability of differentiated products such as high-dose, adjuvanted, cell-based, and recombinant vaccines is boosting the market value through premium pricing.

Influenza Vaccines Market Trends

• A major trend witnessed in the market is the shift toward next‑generation platforms for vaccine development. Traditional egg‑based products are increasingly complemented and, in specific settings, replaced by cell‑based, recombinant, and adjuvanted influenza vaccines, as manufacturers pursue better antigenic match, higher yield, and faster scale‑up.
   
• For instance, in March 2025, the FDA approved an expanded indication for the recombinant influenza vaccine Flublok, lowering its age eligibility from 18+ to 9 years, reflecting growing regulatory and commercial momentum behind next‑generation technologies. This platform diversification is reshaping supply resilience and effectiveness, particularly for high‑risk cohorts and during volatile seasons.
   
• Additionally, global immunization policies and government procurement are strengthening demand. Expanded recommendations for annual vaccination, stockpiling strategies, and institutional purchasing across North America, Europe, and fast‑growing APAC markets are raising baseline volumes and, with them, the incentives for manufacturers to invest in capacity and innovation. This policy tailwind underpins steady market growth through the next decade.
   
• At the same time, manufacturers are addressing historical pitfalls, especially variable efficacy and long lead times. By shifting part of their production to cell‑based/recombinant platforms and integrating enhanced adjuvants, suppliers are working to mitigate antigenic drift risks and compress production cycles, which should translate into more consistent real‑world performance.
   
• Moreover, continuous technology advancement is reducing the time‑to‑market and offering an expanded portfolio of vaccines in the market. mRNA and combination vaccine programs have shown late‑stage progress, signaling a horizon where rapid re‑formulation and co‑administration may enhance coverage, simplify logistics, and improve uptake across adult populations.
   
• Looking ahead, sustained growth is supported by the persistent clinical and economic burden of influenza and the strategic framing of flu vaccination as a biosecurity priority.
   
• With WHO and national agencies reinforcing surveillance, procurement, and equitable access, and with leading manufacturers expanding capacity and pipelines, the market is anticipated to witness strong growth.
   

Influenza Vaccines Market Analysis

Based on the vaccine type, the influenza vaccines market is segmented into inactivated, live attenuated and recombinant. The inactivated segment has asserted its dominance in the market by securing a significant market share of 85.7% in 2025 and is anticipated to grow at a CAGR of 6.9% over the forecast years.
 

• The inactivated influenza vaccines dominated the global market in 2025, owing to their strong safety profile and effectiveness across diverse population groups, including adults and children.
   
• Moreover, inactivated vaccines are the preferred choice for national immunization programs due to their ability to provide immune responses without the risk of viral replication, which becomes suitable for a wide age group, including elderly individuals, pregnant women, immunocompromised patients, and patients suffering from chronic conditions.
   
• On the other hand, the recombinant influenza vaccines segment is anticipated to witness strong growth at a CAGR of 8%, driven by their egg‑free, precision‑designed antigen production and ability to offer consistent performance across seasons, supporting broader protection in diverse age and risk groups.
   

Based on the indication, the influenza vaccines market is classified into quadrivalent and trivalent. The quadrivalent segment accounted for the highest market revenue of USD 7.9 billion in 2025.
 

• Quadrivalent influenza vaccines are the dominating segment due to their ability to provide broader protection against four circulating influenza virus strains, two influenza A strains and both B lineages. This expanded coverage has made quadrivalent vaccines a preferred choice for national immunization programs, as they significantly reduce the risk of strain mismatch and improve overall seasonal preparedness.
   
• Also, quadrivalent vaccines offer a strategic advantage by addressing unpredictable seasonal shifts, thereby improving clinical outcomes, reducing hospitalizations, and strengthening public‑health impact.
   
• The trivalent influenza vaccines segment, on the other hand, was valued at USD 1.1 billion in 2025. These vaccines continue to serve specific market needs, as they offer protection against three strains that include two A strains and a single B lineage and remain relevant in public health programs and procurement models.
   

Based on the technology, the influenza vaccines market is classified into egg-based, cell-based, and recombinant technology. The egg-based segment dominated the market in 2025 and is anticipated to witness growth at a CAGR of 6.8%.
 

• The egg‑based influenza vaccines segment dominated the global market in 2025, supported by its long-term use, established manufacturing infrastructure, proven safety profile, and widespread use across national immunization programs.
   
• Additionally, continuous improvements in antigen yield, purification processes, and quadrivalent formulations have helped maintain the relevance of egg‑based vaccines in an evolving market.
   
• On the other hand, the recombinant technology segment is anticipated to grow at a CAGR of 8.1% between 2026 and 2035.
   
• This segment is emerging as the fastest‑growing technology, driven by its ability to bypass egg‑adaptation issues and enable highly controlled antigen design that supports more consistent influenza vaccine performance across seasons.
   

Based on the flu type, the influenza vaccines market is classified into seasonal and pandemic. The seasonal segment accounted for the highest market revenue in 2025 and is anticipated to reach USD 13 billion by 2035. 
 

• The seasonal influenza vaccines segment is stimulated by the recurring annual burden of seasonal flu outbreaks across all major regions.
• According to United Nations Office for Disaster Risk Reduction (UNDRR), seasonal influenza results in about 3 to 5 million cases of severe illness, stimulating segmental growth.
   
• Seasonal vaccines play a critical role in reducing flu‑related hospitalizations, preventing severe complications, and alleviating pressure on healthcare systems during peak flu months.
   
• In addition, continuous enhancements in dosing options, high‑dose and adjuvanted versions for older adults, and more convenient delivery formats have improved accessibility and increased vaccination uptake.
   

Based on the age group, the influenza vaccines market is classified into pediatric and adult. The pediatric segment accounted for the highest market revenue of USD 7.1 billion in 2025. 
 

• The pediatric segment dominated the market, driven by strong public‑health prioritization and high vaccination uptake among children.
   
• Further, a high incidence of influenza in children, coupled with updated guidelines by various countries for influenza vaccines, is driving the demand for vaccination. For instance, as per the NIH, more than 90 million cases per year occur in children below 5, stimulating the segment dominance.
   
• The dominance of the pediatric vaccines segment is further supported by recommendations for routine annual vaccination against influenza in children, increasing availability of child‑friendly formulations, and widespread adoption of both inactivated and intranasal live attenuated vaccines in pediatric settings.
   
• On the other hand, the adult segment continues to represent a substantial share of the market due to annual vaccination recommendations for working-age individuals, pregnant women, and those with chronic medical conditions.
   

Based on the route of administration, the influenza vaccines market is segmented into injection and nasal spray. The injection segment has asserted its dominance in the market by securing a significant market share of 91.1% in 2025 and is anticipated to grow at a CAGR of 6.8% over the forecast years.
 

• The injection segment continues to dominate the market, due to its wide adoption, positive immunogenicity, and strong focus on global vaccination guidelines.
   
• These influenza vaccines are primarily inactivated formulations and have been the standard option for seasonal immunization due to their established safety profiles.
   
• Moreover, the availability of enhanced versions that include high‑dose, adjuvanted, and cell‑based injectable vaccines has strengthened clinical effectiveness, especially among older adults, stimulating the continued demand for injection-based vaccine delivery.
   
• The nasal spray segment, on the other hand, is emerging as the fastest‑growing route of administration, stimulated by its unique advantages in pediatric populations and individuals with needle aversion.
   

Based on the end use, the influenza vaccines market is classified into hospitals, clinics, and other end users. The hospitals segment held a market share of 73.7% in 2025.
 

• The hospitals segment is further bifurcated into public and private.
   
• Hospitals remain the primary centers for vaccination due to their advanced infrastructure, large‑scale immunization, management of high‑risk populations, and coordination of seasonal vaccination campaigns.
   
• Their dominance is further supported as they are the key sites for public vaccination drives, especially during seasons with elevated disease burden or rapid changes in circulating strains.
   
• The clinics segment, on the other hand, is expected to witness strong growth during the forecast period.
   
• Clinics play an important role in accessibility, convenience, and ability to accommodate high patient turnover during peak vaccination periods, offering counseling, routine monitoring, and administration of certain vaccinations in outpatient settings.
   

North America Influenza Vaccines Market

The North America market dominated the global market with a share of 44.9% in 2025.
 

• North America held a dominant market position in the market owing to its highly developed healthcare infrastructure, along with strong and supportive regulatory approvals for vaccines, and higher adoption to early prevention.
   
• The region’s leadership is reinforced by mature surveillance and policy frameworks that recommend annual vaccination for individuals aged 6 months and older, supporting broad coverage across pediatric, adult, and high‑risk cohorts.
   

The U.S. influenza vaccines market size reached USD 3.5 billion in 2025, growing from USD 3.4 billion in 2024.
 

• The U.S. dominated the North America market, owing to factors such as high burden of influenza and strong CDC recommendations for vaccinations, which are ensuring stable, and high vaccination coverage throughout the country.
   
• For example, for the 2025-2026 U.S. flu season, the CDC estimated at least 15 million illnesses, 180,000 hospitalizations, and 7,400 deaths, and statistics suggested that around 43.1% of adults aged 18 years and older received an influenza vaccination, collectively driving market growth.
   
• Moreover, ongoing innovation and pipeline progress toward combination and mRNA influenza candidates point to sustained technology upgrades and durable market growth.
   

Europe Influenza Vaccines Market

Europe market accounted for USD 2.3 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• The Europe market is stimulated by the high prevalence of flu cases, strong government support for vaccine development, and collaborative research initiatives across the region.
   
• According to European Centre for Disease Prevention and Control (ECDC), about 20% of the region’s population is infected with seasonal influenza each year.
   
• The region also benefits from a well-established network of academic institutions, biotech firms, and regulatory bodies, stimulating innovation and patient access to vaccines.

Germany dominated the Europe market, showcasing strong growth potential.
 

• Germany holds a high market share due to its advanced healthcare infrastructure, strong clinical research ecosystem, and early adoption of vaccines.
   
• Moreover, Germany is home to several leading pharmaceutical and biotech companies actively engaged in vaccine development, maintaining its position as a key innovation hub in the region.
   

Asia Pacific Influenza Vaccines Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 7.5% during the analysis timeframe.
 

• The Asia Pacific region is the fastest‑growing regional market, escalated by expanding healthcare infrastructure, rising vaccination awareness, and government programs that are progressively broadening vaccination coverage.
   
• The region is transitioning from episodic to more programmatic seasonal immunization, creating a continuous demand for influenza vaccine across the region.
   
• Additionally, growing investments in biotechnology, coupled with supportive regulatory reforms in countries such as China and Japan, are creating significant opportunities for market expansion.
   

China influenza vaccines market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• China’s market growth is stimulated by rapid improvements in vaccine uptake and government initiatives to include vaccines in reimbursement lists.
   
• Moreover, urbanization, large high‑risk cohorts, and increasing institutional procurement are stimulating the adoption of seasonal vaccination for premium quadrivalent options in major cities.
   

Latin American Influenza Vaccines Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil is seeing rising influenza cases, significantly driving the vaccine adoption in the country.
   
• In addition, the country’s rapidly growing primary care infrastructure, along with large‑scale public procurement efforts, is strengthening seasonal vaccination uptake, thereby stimulating market demand.
• Additionally, government-backed initiatives to include influenza vaccines in public healthcare coverage are supporting wider clinical adoption.
   

Middle East and Africa Influenza Vaccines Market
 

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market.
 

• Saudi Arabia’s market expansion is driven by strong government-led immunization initiatives, expanding public healthcare infrastructure, and increasing awareness of seasonal influenza prevention.
   
• The country’s Vision 2030 healthcare transformation program is supporting higher vaccine uptake through improved access, preventive care focus, and expanded coverage for high-risk populations.
   

Influenza Vaccines Market Share

The market is moderately consolidated, with a group of leading vaccine manufacturers accounting for a substantial share of global revenues. Top market players, such as Sanofi, AstraZeneca, GlaxoSmithKline, CSL Seqirus, and Sinovac Biotech, collectively accounted for approximately 65% of the global market in 2025, driven by their extensive vaccine portfolios, robust manufacturing capacity, and long-standing participation in national immunization programs worldwide. These companies dominated key segments of the market through broad quadrivalent product offerings, cell‑based vaccines, and diversified production networks that ensure seasonal security of supply. Their leadership is reinforced by strong global distribution frameworks, established procurement relationships with public‑health agencies, and ongoing investments in technology upgrades, including recombinant and cell-based influenza vaccine platforms. 
 

The competitive landscape is further shaped by strategic collaborations, public–private partnerships, and government-backed procurement agreements, enabling leading players to expand manufacturing capacity, improve strain‑selection responsiveness, and strengthen pandemic preparedness. Companies are also actively investing in next‑generation innovations, including mRNA-based influenza vaccines and combination platforms, which are expected to reshape future demand and product differentiation. Lifecycle management strategies such as high‑dose formulations, adjuvant enhancements, and expanded age‑group indications continue to support market depth across adult, pediatric, and high‑risk populations.
 

Influenza Vaccines Market Companies

Prominent players operating in the influenza vaccines industry are as mentioned below:

• AstraZeneca
• Bharat Biotech
• Cadila Healthcare (Zydus Lifesciences)
• CSL Seqirus
• Denka Seiken
• GlaxoSmithKline
• Sanofi
• Serum Institute of India
• Sinovac Biotech
• SK bioscience
• Viatris
• GC Biopharma
• Bio Farma
   
• Sanofi

Sanofi holds a leading position in the influenza vaccines market with a market share of ~17%, supported by its extensive seasonal flu portfolio, including high‑dose, adjuvanted, and recombinant formulations that cater to elderly and high‑risk populations. The company is recognized as one of the top global influenza vaccine manufacturers, contributing significantly to the collective market share held by major players.
 

• AstraZeneca

AstraZeneca plays a notable role in the market, driven by its FluMist/Fluenz, which remains a differentiated option in pediatric and needle‑averse populations. Positioned among the major global players shaping the influenza vaccine landscape, AstraZeneca enhances market competitiveness through innovation in delivery formats and continued expansion of access in multiple regions.
 

• GlaxoSmithKline

GlaxoSmithKline is a key global player in the influenza vaccines market, supported by its broad quadrivalent vaccine portfolio and strong geographic reach through established public‑health partnerships. As one of the dominant manufacturers, GSK consistently ranks among the leading contributors to global influenza vaccine supply.
 

Influenza Vaccines Industry News

• In November 2025, Apriori Bio and ASTAR Infectious Diseases Labs formed a strategic partnership to co‑develop next‑generation self‑amplifying RNA vaccines for seasonal and pandemic influenza. It strengthened both organizations innovation pipelines and future competitiveness in influenza vaccines.
   
• In July 2024, GSK acquired full rights from CureVac to develop and commercialize mRNA influenza and COVID‑19 vaccines under a restructured licensing agreement. It enhanced GSK’s competitiveness in mRNA vaccine development and broadened its influenza technology portfolio.
   
• In February 2024, AstraZeneca completed its acquisition of Icosavax, a U.S. vaccine developer specializing in protein VLP platforms. It enhanced AstraZeneca’s vaccine pipeline and reinforced its position in respiratory viral immunization.
   

The influenza vaccines market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Inactivated
• Live attenuated
• Recombinant

Market, By Indication

• Quadrivalent
• Trivalent

Market, By Technology

• Egg-based
• Cell-based
• Recombinant technology

Market, By Flu Type

• Seasonal
• Pandemic

Market, By Age Group

• Pediatric
• Adults

Market, By Route of Administration

• Injection
• Nasal spray

Market, By End Use

• Hospitals      
  • Public
  • Private
• Clinics 
• Other end users
        

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE